

DAFTAR PUSTAKA

- Airolidi, G. dan Campanini, M., 2008. Fondaparinux. *Italian Journal of Medicine*, **2**: 44–52.
- Andayani, T.M., 2013. *Farmakoekonomi: Prinsip Dan Metodologi*, 1st ed. Bursa Ilmu.
- Artha, I.M.J.R. dan Dwipayana, I.M.P., 2018. Mortality Rate and Its Associated Factors in Patients with Non ST-Elevation-Acute Coronary Syndrome in Bali: Results from A Single Center Registry. *Biomedical and Pharmacology Journal*, **11**: 1895–1901.
- Blick, S.K.A., Orman, J.S., Wagstaff, A.J., dan Scott, L.J., 2008. Spotlight on Fondaparinux Sodium in Acute Coronary Syndromes. *BioDrugs*, **22**: 413–415.
- Bonnesen, K., Szépligeti, S.K., Szentkúti, P., Horváth-Puhó, E., Sørensen, H.T., dan Schmidt, M., 2024. The impact of comorbidity burden on cardiac arrest mortality: A population-based cohort study. *Resuscitation*, **202**: 110352.
- Breen, K., Finnegan, L., Vuckovic, K., Fink, A., Rosamond, W., dan DeVon, H.A., 2020. Greater Mortality, Higher Readmission Rates, and Increased Length of Stay is Associated with Multimorbidity in Patients with Acute Coronary Syndrome: A Systematic Review. *The Journal of cardiovascular nursing*, **35**: E99–E110.
- Buckley, M.M. dan Sorkin, E.M., 1992. Enoxaparin. *Drugs*, **44**: 465–497.
- Bueno, H., 2018. Epidemiology of acute coronary syndromes, dalam: Camm, A.J., Lüscher, T.F., Maurer, G., Serruys, P.W., James, S. (Eds.), *The ESC Textbook of Cardiovascular Medicine*. Oxford University Press, hal. 0.
- Bultas, J. dan Karetová, D., 2011. Low molecular weight heparins - Their significance in current practice. *Interni Medicina pro Praxi*, **13**: 440–444.
- Camilla, P., M, M., A, O., dan R, R., 2012. Cost-effectiveness of fondaparinux in patients with acute coronary syndrome without ST-segment elevation. *Arquivos brasileiros de cardiologia*, **99**: .
- Candradewi, S.F., 2014. 'Analisis Efektivitas dan Biaya Enoxaparin Dibandingkan Dengan Fondaparinux Pada Pasien Dengan Sindrom Koroner Akut'. Universitas Gadjah Mada, Yogyakarta.
- Cestac, P., Bagheri, H., Lapeyre-Mestre, M., Sié, P., Fouladi, A., Maupas, E., dkk., 2003. Utilisation and Safety of Low Molecular Weight Heparins. *Drug Safety*, **26**: 197–207.
- Charlson, M., Szatrowski, T.P., Peterson, J., dan Gold, J., 1994. Validation of a combined comorbidity index. *Journal of Clinical Epidemiology*, **47**: 1245–1251.
- Charlson, M.E., Pompei, P., Ales, K.L., dan MacKenzie, C.R., 1987. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *Journal of Chronic Diseases*, **40**: 373–383.
- Colwell Jr., C.W., Kwong, L.M., Turpie, A.G.G., dan Davidson, B.L., 2006. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. *Journal of Arthroplasty*, **21**: 36–45.

- Çurgunlu, A. dan Tezcan, V., 2004. Coronary artery disease in type 2 diabetes mellitus. *Gogus-Kalp-Damar Anestezi ve Yogun Bakim Dernegi Dergisi*, **10**: 88–93.
- Damluji, A.A., Forman, D.E., Wang, T.Y., Chikwe, J., Kunadian, V., Rich, M.W., dkk., 2023. Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association. *Circulation*, **147**: e32–e62.
- DiPiro, J.T. (Ed.), 2020. *Pharmacotherapy: A Pathophysiologic Approach*, Eleventh edition. ed. McGraw Hill Medical, New York.
- Drosowsky, A. dan Gough, K., 2022. The Charlson Comorbidity Index: problems with use in epidemiological research. *Journal of Clinical Epidemiology*, **148**: 174–177.
- Fareed, J., Hoppensteadt, D., Walenga, J., Iqbal, O., Ma, Q., Jeske, W., dkk., 2003. Pharmacodynamic and pharmacokinetic properties of enoxaparin: Implications for clinical practice. *Clinical Pharmacokinetics*, **42**: 1043–1057.
- Felix, B., Aldooohan, F., Kadirage, H.U., Keelathara Sajeev, S., Kayani, M., Hag Saeed, M.A.I., dkk., 2024. Assessment of the Impact of Comorbidities on Outcomes in Non-ST Elevation Myocardial Infarction (NSTEMI) Patients: A Narrative Review. *Cureus*, **16**: e65568.
- Garcia, D.A., Baglin, T.P., Weitz, J.I., dan Samama, M.M., 2012. Parenteral Anticoagulants. *Chest*, **141**: e24S–e43S.
- Ghodke, M. dan Giri, P., 2023. Consumer Price Index (CPI) – Types & Sources. *Indian Journal of Community Health*, **35**: 520–525.
- Hannon, M.G. dan Lamont, J.G., 2012. Compartment Syndrome Due to Massive Leg Hematoma After Primary Total Hip Arthroplasty. A Previously Unreported Complication of Fondaparinux. *Journal of Arthroplasty*, **27**: 1414.e9–1414.e11.
- Hapsari, D. C., 2014. 'Efektivitas dan Keamanan Penggunaan Fondaparinux Dibandingkan Enoxaparin Pada Pasien Sindroma Koroner Akut Tanpa Elevasi Segment ST'. Universitas Gadjah Mada, Sleman, DIY.
- Held, P.H., Yusuf, S., dan Furberg, C.D., 1989. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. *BMJ (Clinical research ed.)*, **299**: 1187–1192.
- Hulot, J.-S., Vantelon, C., Urien, S., Bouzamondo, A., Mahé, I., Ankri, A., dkk., 2004. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. *Therapeutic Drug Monitoring*, **26**: 305–310.
- Iqbal, Z. dan Cohen, M., 2011. Enoxaparin: a pharmacologic and clinical review. *Expert Opinion on Pharmacotherapy*, **12**: 1157–1170.
- Kementerian Kesehatan RI, 2013. *Pedoman Penerapan Kajian Farmakoekonomi*. Katalog Dalam Terbitan Kemenkes RI, Jakarta.
- Kementerian Kesehatan RI, 2020. *Petunjuk Teknis Penilaian Farmakoekonomi Dalam Seleksi Obat*. Kemenkes.
- Kimura, T., Akahori, H., Asakura, M., Nakao, K., Ozaki, Y., Kimura, K., dkk., 2021. Impact of Age on Gender Difference in Long-term Outcome of

- Patients With Acute Myocardial Infarction (from J-MINUET). *American Journal of Cardiology*, **142**: 5–13.
- Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., dkk., 2020. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *European Heart Journal*, **41**: 407–477.
- Kuehnemund, L., Koeppe, J., Feld, J., Wiederhold, A., Illner, J., Makowski, L., dkk., 2021. Gender differences in acute myocardial infarction—A nationwide German real-life analysis from 2014 to 2017. *Clinical Cardiology*, **44**: 890–898.
- Kytö, V., Sipilä, J., dan Rautava, P., 2015. Association of age and gender with risk for non-ST-elevation myocardial infarction. *European Journal of Preventive Cardiology*, **22**: 1003–1008.
- Lacy, C.F., 2015. *Drug Information Handbook: A Clinically Relevant Resource for All Healthcare Professionals*, 24th edition. ed. Lexi-Comp Inc.
- Lee, C.-H., Fang, C.-C., Tsai, L.-M., Gan, S.-T., Lin, S.-H., dan Li, Y.-H., 2018. Patterns of Acute Myocardial Infarction in Taiwan from 2009 to 2015. *American Journal of Cardiology*, **122**: 1996–2004.
- Lemeshow, S., Lwanga, S.K., dan Lachenbruch, P.A., 1991. Sample Size Determination in Health Studies: A Practical Manual. *Journal of the American Statistical Association*, **86**: 1149.
- McCabe, C., Paulden, M., Awotwe, I., Sutton, A., dan Hall, P., 2020. One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit. *Pharmacoeconomics*, **38**: 135–141.
- Mehta, L.S., Beckie, T.M., DeVon, H.A., Grines, C.L., Krumholz, H.M., Johnson, M.N., dkk., 2016. Acute Myocardial Infarction in Women. *Circulation*, **133**: 916–947.
- Mehta, S.R., Eikelboom, J.W., Demers, C., Maggioni, A.P., Commerford, P.J., dan Yusuf, S., 2005. Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: Incidence, predictors, and clinical outcomes. *Canadian Journal of Physiology and Pharmacology*, **83**: 98–103.
- Michelson, A.D., 2013. *Platelets*, 3rd ed. ed. Academic Press, Amsterdam.
- Muharram, F.R., Multazam, C.E.C.Z., Mustofa, A., Socha, W., Andrianto, Martini, S., dkk., 2024. The 30 Years of Shifting in The Indonesian Cardiovascular Burden—Analysis of The Global Burden of Disease Study. *Journal of Epidemiology and Global Health*, .
- Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., dkk., 1981. A method for estimating the probability of adverse drug reactions. *Clinical Pharmacology and Therapeutics*, **30**: 239–245.
- OASIS-5, 2006. Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. *New England Journal of Medicine*, **354**: 1464–1476.
- PERKI, 2015. *Pedoman Tatalaksana Sindrom Koroner Akut*, Edisi 3. ed. Jurnal Kardiologi Indonesia.
- Permsuwan, U., Chaiyakunapruk, N., Nathisuwan, S., dan Sukonthasarn, A., 2015. Cost-Effectiveness Analysis of Fondaparinux vs Enoxaparin in Non-ST

- Elevation Acute Coronary Syndrome in Thailand. *Heart, Lung and Circulation*, **24**: 860–868.
- Pratama, V., 2022. 'Analisis Efektivitas Biaya Antara Ampisilin/Sulbaktam dan Non-Ampisilin/Sulbaktam Pada Pasien Infeksi Kaki Diabetik Rawat Inap di RSUPN Dr. Cipto Mangunkusumo', *Thesis*, . Universitas Indonesia, Jakarta.
- Purnami, I.D., Nugrahaeni, A.R.D., dan Khasanah, 2023. Analisis Efektivitas Biaya Terapi Enoxaparin dan Fondaparinux Pada Pasien Jantung N-STEMI Rawat Inap di RSD K.R.M.T. Wongsonegoro. *Indonesian Journal of Medical and Pharmaceutical Science*, **2**: 21–26.
- Raposo, L., Aguiar, C., Ferreira, J., Gonçalves, P.D.A., Ferreira, A., dan Da Silva, J.A., 2010. Myocardial revascularization reverses adverse outcome in non-ST-elevation acute coronary syndromes complicated by heart failure. *Revista Portuguesa de Cardiologia*, **29**: 1131–1142.
- Rautenberg, T., Gerritsen, A., dan Downes, M., 2020. Health economic decision tree models of diagnostics for dummies: A pictorial primer. *Diagnostics*, **10**: .
- Rogers, P., Merenda, C., Araujo, R., Lee, C., Lolic, M., Zhang, Y., dkk., 2024. Developing a Charlson Comorbidity Index for the American Indian Population Using the Epidemiologic Data from the Strong Heart Study. *Journal of Racial and Ethnic Health Disparities*, .
- Rogers, W.J., Frederick, P.D., Stoehr, E., Canto, J.G., Ornato, J.P., Gibson, C.M., dkk., 2008. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. *American Heart Journal*, **156**: 1026–1034.
- Ross Terres, J.A., Lozano-Ortega, G., Kendall, R., dan Sculpher, M.J., 2015. Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5). *BMC cardiovascular disorders*, **15**: 180.
- Rossello, X., Dan, G.-A., Dweck, M.R., Galbraith, M., Hinterbuchner, L., Jankowska, E.A., dkk., 2023. 2023 ESC Guidelines for the management of acute coronary syndromes.
- Sculpher, M.J., Lozano-Ortega, G., Sambrook, J., Palmer, S., Ormanidhi, O., Bakhai, A., dkk., 2009. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. *American Heart Journal*, **157**: 845–852.
- Soeiro, A.D.M., Silva, P.G.M.D.B.E., Roque, E.A.D.C., Bossa, A.S., César, M.C., Simões, S.A., dkk., 2016. Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data. *Arquivos Brasileiros de Cardiologia*, .
- Soukoulis, V., Boden, W.E., Smith, S.C., dan O’Gara, P.T., 2014. Non-Antithrombotic Medical Options in ACS: Old Agents and New Lines on the Horizon. *Circulation research*, **114**: 1944–1958.

- Subahi, A., Abdullah, A., Yassin, A.S., Abubakar, H., Abugroun, A., Eigbire, G., dkk., 2019. Impact and Outcomes of Patients with Congestive Heart Failure Complicating Non-ST-Segment Elevation Myocardial Infarction, Results from a Nationally-Representative United States Cohort. *Cardiovascular Revascularization Medicine*, **20**: 659–662.
- Sullivan, G.M. dan Feinn, R., 2012. Using Effect Size—or Why the *P* Value Is Not Enough. *Journal of Graduate Medical Education*, **4**: 279–282.
- Sundargowda, S.A., Halumane, K.S., Kadiri, S.K., dan Khobragade, D.S., 2024. Odd Consequences of Dysglycemia in Acute Coronary Syndrome. *Current Drug Therapy*, .
- Szummer, K., Oldgren, J., Lindhagen, L., Carrero, J.J., Evans, M., Spaak, J., dkk., 2015. Association Between the Use of Fondaparinux vs Low-Molecular-Weight Heparin and Clinical Outcomes in Patients With Non–ST-Segment Elevation Myocardial Infarction. *JAMA*, **313**: 707–716.
- Tessy, D.B., Pramudyo, M., dan Cool, C.J., 2021. Characteristics of In-Hospital Mortality among Patients with Acute Coronary Syndrome: A Single-Center Study in West Java, Indonesia. *Althea Medical Journal*, **8**: 99–103.
- Timmis, A., Kazakiewicz, D., Townsend, N., Huculeci, R., Aboyans, V., dan Vardas, P., 2023. Global epidemiology of acute coronary syndromes. *Nature Reviews Cardiology*, **20**: 778–788.
- Umerah, C. o dan Momodu, I.I., 2025. Anticoagulation, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- White, J.A., Case, K.E., dan Pratt, D.B., 2012. *Principles of Engineering Economic Analysis*, 6th edition. ed. Wiley, Hoboken, NJ.
- Zhang, H. dan Yu, M., 2022. Clinical Characteristics of Young Patients With Non-ST-segment Elevation Myocardial Infarction. *Chinese Circulation Journal*, **37**: 914–919.
- Zhang, Y., Zhang, M., Tan, L., Pan, N., dan Zhang, L., 2019. The clinical use of Fondaparinux: A synthetic heparin pentasaccharide, dalam: *Progress in Molecular Biology and Translational Science*. Elsevier, hal. 41–53.